Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence

Tyrosine kinase inhibitor (TKI) use is critical in the care of patients with chronic myeloid leukemia (CML). Quantitative polymerase chain reaction (qPCR) testing for BCR-ABL1 every 3 months during the first year of TKI treatment is recommended to assure achievement of milestone response goals. Real...

Descripción completa

Detalles Bibliográficos
Autores principales: Shallis, Rory M., Wang, Rong, Zeidan, Amer M., Huntington, Scott F., Neparidze, Natalia, Stempel, Jessica M., Mendez, Lourdes M., Di, Mengyang, Ma, Xiaomei, Podoltsev, Nikolai A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338212/
https://www.ncbi.nlm.nih.gov/pubmed/36939371
http://dx.doi.org/10.1182/bloodadvances.2022009074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338212/
https://www.ncbi.nlm.nih.gov/pubmed/36939371
http://dx.doi.org/10.1182/bloodadvances.2022009074

Ejemplares similares